Dow Down0.52% Nasdaq Up0.08%

Clovis Oncology, Inc. (CLVS)

16.87 Up 0.17(1.02%) 1:15PM EDT - Nasdaq Real Time Price
ProfileGet Profile for:
Clovis Oncology, Inc.
5500 Flatiron Parkway
Suite 100
Boulder, CO 80301
United States - Map
Phone: 303-625-5000
Fax: 303-245-0360

Index Membership:N/A
Full Time Employees:304

Business Summary 

Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. It is developing three product candidates, which include Rociletinib, an oral epidermal growth factor receptor and mutant-selective covalent inhibitor that is under review with the U.S. and E.U. regulatory authorities for the treatment of non-small cell lung cancer; Rucaparib, an oral inhibitor of poly polymerase, which is in advanced clinical development for the treatment of ovarian cancer; and Lucitanib, an oral inhibitor of the tyrosine kinase that is in Phase II development for the treatment of breast cancers. It has license agreements with Advenchen Laboratories LLC, Avila Therapeutics, Inc., and Pfizer Inc.; collaboration and license agreement with Les Laboratoires Servier; a drug discovery collaboration agreement with Array BioPharma Inc.; and collaboration with Foundation Medicine, Inc. Clovis Oncology, Inc. was founded in 2009 and is headquartered in Boulder, Colorado.

Key Statistics

Company Websites 
Home Page
Search Yahoo! for:
More on Clovis Oncology, Inc.

Corporate Governance 
Clovis Oncology, Inc.’s ISS Governance QuickScore as of May 1, 2016 is 8. The pillar scores are Audit: 2; Board: 4; Shareholder Rights: 8; Compensation: 8.
Brought to you by Institutional Shareholder Services (ISS)

Key Executives 
Mr. Patrick J. Mahaffy MA, 53
Co-Founder, Chief Exec. Officer, Pres and Director
Dr. Gillian C. Ivers-Read BSc, 62
Co-Founder, Chief Regulatory Officer and Exec. VP of Technical Operations
Dr. Lindsey Rolfe BSc, MB ChB, MRCP, FFPM, 48
Chief Medical Officer and Exec. VP of Clinical, Preclinical Devel. & Pharmacovigilance
Mr. Daniel W. Muehl CPA, 52
Principal Financial Officer, Principal Accounting Officer and VP of Fin.
Ms. Breanna Burkart ,
Sr. Director of Investor Relations
Amounts are as of Dec 31, 2015 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in USD.
View Insiders